Modulation Therapeutics Incoporated

Modulation Therapeutics is developing a novel, first in class drug for multiple myeloma and other cancers that metastasize to bone.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Tampa, FL, USA
  • Currency USD
  • Founded June 2011
  • Employees 2
  • Website modulationtherapeutics.com

Company Summary

The company is developing a novel first in class peptide mimetic drug called MT-101 for multiple myeloma and other cancers that metastasize to bone. MT-101 has a novel mechanism of action that differentiates it from all other existing drugs for myeloma. Preclinical data show promising single agent and combination (Velcade) efficacy with no overt toxicity in vivo. We seek investors to fund development of MT-101 from IND through Phase I/IIa.

Team

  • Mark L McLaughlin
    Executive Vice President

  • Lori Hazlehurst
    President

  • Michael Cerio
    Interim CEO

    Michael Cerio, MBA, MS is interim CEO of Modulation Therapeutics. Previously he was Senior Director of Business Development for Genzyme Corporation and led licensing and M&A for the Genzyme Genetics business unit. He previously led business development activities for BG Medicine and Genaissance Pharmaceuticals. He received his MBA from Columbia University School of Business and an MS in Molecular Biology from University of Connecticut.

  • Mark McLaughlin

Advisors

  • John Igoe, Edwards Wildman Palmer, LLP; 525 Okeechobee Boulevard, Suite 1600; West Palm Beach, Florida 33401
    Lawyer
    Unconfirmed
    Carr, Riggs & Ingram, LLC; 2111 Drew Street; Clearwater, FL 33765
    Accountant
    Unconfirmed

Previous Investors

  • Multiple Myeloma Research Foundation
    Unconfirmed

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free